IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $46.00 Average PT from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received an average rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $46.3333.

A number of research firms recently weighed in on IDYA. JPMorgan Chase & Co. upped their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Mizuho raised their price target on shares of IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 11th. BTIG Research reiterated a “buy” rating and issued a $62.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Guggenheim assumed coverage on IDEAYA Biosciences in a report on Thursday, September 18th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Royal Bank Of Canada boosted their price target on IDEAYA Biosciences from $38.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in IDEAYA Biosciences by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after purchasing an additional 353 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of IDEAYA Biosciences by 16.1% in the third quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after acquiring an additional 537 shares during the last quarter. CWM LLC boosted its holdings in shares of IDEAYA Biosciences by 33.0% in the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after acquiring an additional 782 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its position in IDEAYA Biosciences by 7.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock worth $257,000 after acquiring an additional 881 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Down 3.8%

Shares of NASDAQ IDYA opened at $36.43 on Friday. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -19.59 and a beta of 0.05. IDEAYA Biosciences has a one year low of $13.45 and a one year high of $39.28. The business has a fifty day simple moving average of $33.90 and a 200 day simple moving average of $28.13.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.